Skip to main content

Table 1 Patient characteristics: Full Analysis Set

From: Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy

Variable RGB-02
(N = 121)
Reference
(N = 117)
Total
(N = 238)
Race [n (%)]
 White 120 (99.2) 117 (100) 237 (99.6)
 Asian 1 (0.8) 0 1 (0.4)
Age (years)
 Mean (std) 51.0 (8.20) 51.2 (9.56) 51.1 (8.88)
Weight (kg)
 Mean (std) 72.17 (14.049) 74.83 (15.240) 73.48 (14.676)
Height (cm)
 Mean (std) 163.3 (6.58) 163.5 (6.29) 163.4 (6.43)
BSA (m2)    
 Mean (std) 1.791 (0.1718) 1.815 (0.1812) 1.803 (0.1765)
Stage of disease [n (%)]
 Stage IIB 58 (47.9) 56 (47.9) 114 (47.9)
 Stage III 61 (50.4) 60 (51.3) 121 (50.8)
Chemotherapy treatment [n (%)]
 Neoadjuvant 51 (42.1) 58 (49.6) 109 (45.8)
 Adjuvant 70 (57.9) 59 (50.4) 129 (54.2)
  1. BSA body surface area; std.standard deviation